Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant

$6.65M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Marker Therapeutics, Inc.
Country	United States
Start Date	Aug 10, 2023
End Date	Jul 31, 2026
Duration	1,086 days
Number of Grantees	2
Roles	Co-Investigator; Principal Investigator
Data Source	NIH (US)
Grant ID	`10901992`

Grant Description

ABSTRACT

This Phase II application will advance MT-401, a novel multi-tumor associated antigen (mTAA)-specific T cell

product for the treatment of acute myeloid leukemia (AML) and other cancers.

In the USA, ~3,500 AML patients receive hematopoietic stem cell therapy (HSCT) every year, but overall survival

remains